Rationale: With combination of multiple techniques, we have successfully characterized unique, complex chromosomal changes in a patient with chronic lymphocytic leukemia (CLL), a lymphoproliferative disorder.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is a genetically heterogeneous neoplasm characterized by the progressive accumulation of CD5+ mature B cells in bone marrow, lymph nodes, and blood. CLL is the most common leukemia in adults in Western countries and the clinical course of disease ranges from a few months of the diagnosis to ≥20 years. [1, 2] The frequently CLL-associated cytogenetic abnormalities include trisomy 12 (10%-20%), del11q22-q23 (5%-20%), and del13q14 (50%). In addition, del17p13 involving deletion of the tumor suppressor gene TP53 occurs in <10% of CLL at diagnosis but up to 30% in refractory cases. Patients with del17p demonstrate aggressive diseases and have very poor prognoses. [3] [4] [5] [6] [7] It has been reported that chromosomal translocations involving immunoglobulin heavy chain locus (IGH) rearrangement on 14q32 are relatively infrequent in CLL with a frequency of 4%. [4] However, recent studies have revealed that translocations involving IGH rearrangements occur at a very high incidence rate and significantly affects survival of CLL patients. [8] [9] [10] The most frequent translocation in CLL is t(14;19) (q32;q13), which juxtaposes IGH and BCL3 resulting in overexpression of BCL3 [11] and is usually associated with unfavorable clinical outcome and trisomy 12. [8, 12] It was proposed that these 2 changes might cooperate for malignant transformation. [13] In contrast, patients with del(13q) have a better survival than the patients with other cytogenetic abnormalities. [4] Furthermore, t(2;14)(p13;q32) is also a recurrent chromosomal change in CLL. [13] Chromosomal translocations are regarded as an important prognostic indicator and are always associated with shorter survival in B-CLL patients. [8] Recently, several alternate translocations, such as t(4;14)(p16;q32) to generate FGFR3/IGH, t(11;14)(q13;q32) to form CCND1/IGH, t(14;18)(q32;q21) to produce IGH/BCL2 fusion, and t(18;22)(q21;q11) have been identified and provided further insights into the pathogenesis of CLL. [12] [13] [14] [15] However, complex variant translocations may occur in CLL but have been rarely reported.
In the present study, as confirmed by cytogenetic analysis, we report a patient carrying the classical t(14;19)(q32;q13.3) as well as a novel 3-way translocation t(2;14;11)(p16.1;q32;q23), trisomy 12, and del(13q14). Importantly, we revealed a cryptic gain of chromosome 4p16.2 besides trisomy 12 and del (13q14.11-q21) in this patient. This study was approved by the institutional review board (IRB) at the University of Oklahoma Health Sciences Center (IRB number: 6299; Oklahoma City, OK).
Case report

Clinical characteristics
A 43-year-old female was admitted to the University of Oklahoma Health Sciences Center where she was diagnosed with CLL owing to weight loss and lymphadenopathy. Her hemoglobin and platelet counts were 12.8 g/dL (normal range, 12-16 g/dL) and 158 Â 10 3 cells/mL (140-440 Â 10 3 cells/mL), respectively. Her white blood cell count was 21.81 Â 10 3 cells/mL (4-11 Â 10 3 cells/mL) with relative and absolute lymphocytosis of 67% (15%-46%) and 15.7 Â 10 3 cells/mL (0.6-5.1 Â 10 3 cells/ mL), respectively. Flow cytometric analysis found that her 75% monoclonal B-cells showed lambda light chain restriction of moderate intensity; her immunophenotype were as follows:
2.2. Cytogenetics, fluorescence in situ hybridization, and array comparative genomic hybridization analyses At diagnosis, the patient's B-cells were subjected to karyotype analyses. The results revealed that 25% (5/20) of the metaphase chromosome displayed a variant translocation among chromosomes 2, 11, and 14, and a translocation between 2 chromosomes 14 and 19 as well as +12 and del(13)(q14.11-q21). The karyotype was designated as 47, XX, t(2;14;11) (p16.1;q32;q23), +12, del (13)(q14.11q21), t(14;19) (q32;q13.3) (Fig. 1) .
Fluorescence in situ hybridization (FISH) analyses were performed in the uncultured and cultured cells using the LSI IGH and LSI MLL dual color break-apart rearrangement probes (Abbott Molecular, Inc., Des Plaines, IL) and LSI BCL11A and LSI BCL3 dual color break-apart rearrangement probes (Empire Genomics, Inc., Buffalo, NY). The uncultured cells were also tested using CLL panel (Abbott Molecular, Inc., Des Plaines, IL). All the experimental procedures followed the manufacturers' instructions.
On uncultured interphase cells, FISH did not reveal t(11;14) (q13;q32), t(14;18)(q32;q21), del(6)(q23), del (11) Analyses of karyotyping and FISH results from metaphase cells showed that 3'IGH signals were located on both der(14) and 5'IGH were translocated to der(11) and der (19) , respectively (Fig. 3A) ; 5'BCL3 signal was located on der(19) and 3'BCL3 was translocated to der (14) (Fig. 3B) ; 5'BCL11A signal was located on der(2) and 3'BCL11A was translocated to der (14) (Fig. 3C) ; 5'MLL signal was located on der(11) and 3'MLL was translocated to der(2) (Fig. 3D) . Taken together, these analyses in metaphase cells confirmed the complex translocations among chromosomes 2, 11, and 14 as well as chromosomes 14 and 19 ( Fig. 3E) .
Further array comparative genomic hybridization (CGH) analyses on the patient's DNA sample revealed the presence of an extra chromosome 12 and deletion of 13q14.11-q21, which (Fig. 4) , which plays a pivotal role in early hematopoietic development and malignancy transformation.
Discussion
The case reported here is unique and particularly interesting, as 2 balanced translocations including t(14;19)(q32;q13.3)/IGH; BCL3 and t(2;14;11) (p16.1;q32;q23)/BCL11A;IGH;MLL were observed simultaneously in one patient in addition to trisomy 12 and del(13q). In addition, we detected a microduplication in 4p16.2 involving the MSX1 gene that plays an important role during early hematopoiesis. Importantly, we found a biallelic rearrangement of IGH (14q32) with partner genes BCL11A, MLL, and BCL3 in our case. Translocations involving IGH not only promote pathogenesis but also predict a poor prognosis of B-cell malignancies such as t (8;14)(q24;q32)(MYC/IGH) in Burkitt lymphoma (BL); t(11;14) (q13;q32) (CCND1/IGH) in mantle cell lymphoma (MCL); and t (14;18)(q32;q21) (IGH/BCL2) in follicular lymphoma (FL). [8] The cases with concomitant t(2;14) and t(14;19) translocations have previously been reported, [16] and they are always regarded as a rare recurrent chromosomal changes associated with atypical cytology, trisomy 12, and a progressive disease in CLL. [13, 17, 18] The present study is the first report of a CLL case with a complex variant translocation involving 3 chromosomes 2, 11, 14 named t(2;14;11)(p16.1;q32;q23)/BCL11A;IGH;MLL, especially concurrent with t(14;19)(q32;q13.3)/IGH;BCL3. In contrast to MYC/IGH, CCND1/IGH and IGH/BCL2, the roles for IGH;BCL3 and BCL11A;IGH;MLL fusions in CLL remain poorly understood; however, it is possible the target genes that become overexpressed or gained new functions may be relevant to the poor prognosis of CLL.
The MLL gene rearrangement often occurs in acute myelocytic leukemia (AML), acute lymphoblastic leukemia, and myelodysplastic syndrome. In hematologic malignancies such as CLL, the most common abnormality is the deletion of the MLL(11q23), [19] whereas the MLL gene rearrangement has not been previously observed in CLL. In this study, we revealed this interesting 3-way translocation of the MLL gene rearrangement; whether it contributes to the leukemia progression or even an unfavorable prognosis in CLL warrants further investigation. It is widely believed that presence of only the IGH rearrangement is not sufficient to induce tumorigenesis, and acquisition of additional genetic aberrations is necessary for malignant transformation. [8] Trisomy 12, observed in this case, is one such genetic anomaly. The cytogenetic abnormality of trisomy 12 associated with intermediate prognosis is observed in up to 50% of IGH/BCL3-positive B-CLLs and was considered to act cooperatively with t(14;19) in leukemogenesis. [20] Interestingly, however, it was reported that patients with 13q deletions as a sole abnormality had the longest estimated survival times compared with other cytogenetic abnormalities. [4, 21] Moreover, miR-15a and miR-16-1 locate in this region, and negatively regulate BCL2 expression at a posttranscriptional level. [22] MSX1 was found to be overexpressed in cell lines derived from MCL and leukemia AML as well as in 3% of patients with MCL and AML. [23] In the present study, array CGH revealed a cryptic gain of MSX1 gene besides trisomy 12 and del(13q14.11-q21), which has not been reported previously in CLL. These data suggest an oncogenic role for MSX1 in leukemogenesis.
In summary, we reported a rare case of an adult CLL patient with the coexistence of classical IGH/BCL3 translocation and a three-way variant translocation BCL11A/IGH/MLL, as well as trisomy 12 and del(13q). Furthermore, a cryptic genomic alteration involving leukemia-related MSX1 gene was found in this case at the level of the array CGH. 
